Aromatase inhibitors as endocrine modulators: from breast cancer therapy to male off-label use and doping practice.
Aromatase inhibitors (AIs) suppress estrogen biosynthesis by blocking the conversion of androgens to estrogens. Although they are established endocrine therapies in postmenopausal breast cancer, their mechanism has led to off-label and non-medical use in men, including performance-enhancing drug practices, post-cycle t...